TNF and interstitial lung disease: Although treatments were not recorded for all patients, use of corticosteroids, methotrexate and biological therapies (tumor necrosis factor alpha inhibitors, rituximab, tocilizumab and/or abatacept) reported equally among RA-ILD patients (26, 25, and 23 patients, respectively).